Methods to generate genetically engineered mouse models of soft tissue sarcoma
RD Dodd, L Añó, JM Blum, Z Li, D Van Mater… - Mouse Models of …, 2015 - Springer
RD Dodd, L Añó, JM Blum, Z Li, D Van Mater, DG Kirsch
Mouse Models of Cancer: Methods and Protocols, 2015•SpringerWe discuss the generation of primary soft tissue sarcomas in mice using the Cre-loxP
system to activate conditional mutations in oncogenic Kras and the tumor suppressor p53
(LSL-Kras G12D/+; p53 flox/flox). Sarcomas can be generated either by adenoviral delivery
of Cre recombinase, activation of transgenic Cre recombinase with tamoxifen, or through
transplantation of isolated satellite cells with Cre activation in vitro. Various applications of
these models are discussed, including anticancer therapies, metastasis, in vivo imaging …
system to activate conditional mutations in oncogenic Kras and the tumor suppressor p53
(LSL-Kras G12D/+; p53 flox/flox). Sarcomas can be generated either by adenoviral delivery
of Cre recombinase, activation of transgenic Cre recombinase with tamoxifen, or through
transplantation of isolated satellite cells with Cre activation in vitro. Various applications of
these models are discussed, including anticancer therapies, metastasis, in vivo imaging …
Abstract
We discuss the generation of primary soft tissue sarcomas in mice using the Cre-loxP system to activate conditional mutations in oncogenic Kras and the tumor suppressor p53 (LSL-KrasG12D/+; p53flox/flox). Sarcomas can be generated either by adenoviral delivery of Cre recombinase, activation of transgenic Cre recombinase with tamoxifen, or through transplantation of isolated satellite cells with Cre activation in vitro. Various applications of these models are discussed, including anticancer therapies, metastasis, in vivo imaging, and genetic requirements for tumorigenesis.
Springer
